Zinc supplementation in prediabetes: A randomized double-blind placebo-controlled clinical trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

This study evaluated the effects of zinc supplementation on glycemic control, other cardiometabolic and anthropometric parameters, and disease progression in prediabetes.

Who Took Part

The abstract describes 200 subjects taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Subjects were evaluated at baseline and at 1, 3, 6, and 12 months.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Blinding on both sides kept the subjects and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

The primary outcome was the change in glycemic control from baseline.

Multiple regression analyses were performed, with change in outcome variables after intervention from baseline used as continuous dependent variables.

What Was Measured

This study evaluated the effects of zinc supplementation on glycemic control, other cardiometabolic and anthropometric parameters, and disease progression in prediabetes.

The subject headings attached to it are Biomarkers, Blood Glucose, Diabetes Mellitus, Type 2, Dietary Supplements, Disease Progression, Glucose Tolerance Test and Health Status.

Author keywords: insulin resistance, prediabetes, zinc supplementation, 糖尿病前期, 胰岛素抵抗 and 血糖.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 200 subjects.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Journal of diabetes), a journal based in Australia.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.